IS THIS NCYT TEST4 Sep 2020 01:36
The government is also investing in other kinds of rapid tests using nasal swabs, which – if they work well enough – will overcome the issue of sometimes long turnaround times for the swab tests that have to go to labs. The government’s target is to have all tests reported within 24 hours, so that contacts of people who are infected can be reached quickly to reduce the risk that they may spread the virus.
PART OF
2000 patient trial using Novacyt's testing system
Wed, 22nd Jul 2020 15:30
The randomised clinical trial, recruiting up to 2,000 residents in 50 care homes across east London, is being led by Professor Jo Martin, President of the Royal College of Pathologists and Professor of Pathology at Queen Mary University of London. The study is using a mobile or near-patient testing (NPT) system for COVID-19 developed by Novacyt (further detail below), which comprises the Company's COVID-19 polymerase chain reaction (PCR) test, direct-to-PCR RNA extraction kit (exsig™ Direct), and portable testing instruments (Q16 and Q32 instruments), to ensure reliable results are received within an hour of testing.
The clinical trial team comprises researchers, medical students and laboratory experts from Queen Mary and Novacyt. Daily testing, using Novacyt's NPT system, is being trialled for residents, staff and visitors in 25 care homes. As the comparator, the other 25 care homes will receive standard central laboratory testing once a week.
As part of the clinical trial, the effectiveness of mid-nose nasal swabs compared to invasive nasopharyngeal swabs will be evaluated to support ease of use, lower levels of discomfort and demonstrate more reproducible data.
Sign In
Follow the stocks
